StephenJNogaMDPh.D.

PubMed

• 1 citations
  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup ...
  Cindy Weinstein, Karin Jordan, Stuart A. Green, S. Khanani, Elizabeth Beckford-Brathwaite, Waldimir Vallejos, Annpey Pong, Stephen J. Noga, Bernardo Leon Rapoport> ;BMC Cancer. 2020 Sep 25
• 8 citations
  Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
  Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
• 13 citations
  Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
  David Merola, Candice Yong, Stephen J. Noga, Kenneth M. Shermock> ;Journal of Managed Care & Specialty Pharmacy. 2018 Sep 24
• 4 citations
  Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a ran...
  Cindy Weinstein, Karin Jordan, Stuart A. Green, Elber Camacho, S. Khanani, Elizabeth Beckford-Brathwaite, Annpey Pong, Stephen J. Noga, Bernardo Leon Rapoport> ;Supportive Care in Cancer. 2018 May 28
• 1 citations
  Factors associated with second‐line triplet therapy in routine care in relapsed/refractory multiple myeloma
  Parameswaran Hari, Dorothy Romanus, H. J. Henk, L. K. Becker, Stephen J. Noga, Vicki A. Morrison> ;Journal of Clinical Pharmacy and Therapeutics. 2018 Feb 1
• 28 citations
  Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United ...
  Parameswaran Hari, Dorothy Romanus, Antonio Palumbo, Katarina Luptakova, Robert M. Rifkin, Linh Tran, Aditya Raju, Eileen Farrelly, Stephen J. Noga, Marlo Blazer, Ajai...> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Feb 1
• 27 citations
  Treating Multiple Myeloma Patients With Oral Therapies
  Shaji Kumar, Ravi Vij, Stephen J. Noga, Deborah Berg, Lonnie Brent, Lawrence Dollar, Ajai Chari> ;Clinical Lymphoma, Myeloma & Leukemia. 2017 May 1
• 47 citations
  Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, d...
  Cindy Weinstein, Karin Jordan, Stuart A. Green, E. Camacho, S. Khanani, Elizabeth Beckford-Brathwaite, Waldimir Vallejos, L. Liang, Stephen J. Noga, Bernardo Leon Rapo...> ;Annals of Oncology. 2016 Jan 1
• 69 citations
  Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial
  Ying Guo, Desiree Jones, J. Lynn Palmer, Arthur D. Forman, Shaker R. Dakhil, Maria R. Velasco, Matthias Weiss, Paul B. Gilman, Glenn Mills, Stephen J. Noga, Cathy Eng,...> ;Supportive Care in Cancer. 2014 May 1
• 33 citations
  A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
  James R. Berenson, James Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, Kenneth Dressler, Hassan H. Ghazal, Saad Jamshed, Edwin Kingsley, Wael A. Harb, Stephen J...> ;Annals of Hematology. 2014 Jan 1
• 46 citations
  Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
  James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel-Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward...> ;British Journal of Haematology. 2013 Feb 1
• 327 citations
  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple my...
  Shaji Kumar, Ian W. Flinn, Paul G. Richardson, Parameswaran Hari, Natalie S. Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, R.M. Rifkin, Jeffrey L. ...> ;Blood. 2012 May 10
• A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy.
  Guo Y, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch M> ;J. Clin. Oncol.. 2011-05-20
• Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.
  Berenson JR, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Swift R, Bensen-Kennedy D> ;J. Clin. Oncol.. 2011-05-20
• PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diff...
  Leonard J, Reeves J, Ferhanoglu B, Doner KT, Eom H, Flinn IW, Raposo J, Chowhan NM, Suh C, Noga S, Tumyan G, Aung S, Hajdenberg J, Ulrich BK, Pendergrass KB, Mulligan ...> ;J. Clin. Oncol.. 2011-05-20
• 65 citations
  Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
  Shaji Kumar, Ian W. Flinn, Stephen J. Noga, Parameswaran Hari, R.M. Rifkin, Natalie S. Callander, M Bhandari, Jeffrey L. Wolf, Cristina Gasparetto, Amrita Krishnan, D ...> ;Leukemia. 2010 May 27
• 45 citations
  Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
  Raman Sood, Harry Carloss, Robert Kerr, Jose V. Lopez, Martin W. Lee, Mark Druck, Ian B. Walters, Stephen J. Noga> ;American Journal of Hematology. 2009 Oct 1
• Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.
  Matous J, Letzer J, Rosen P, Noga S, Fowler N, Smith S, Amin B, Shi H, Parasuraman S, Cheson B> ;J. Clin. Oncol.. 2009-05-20
• Are comorbidities present in non-Hodgkin's lymphoma (NHL) patients (pts) enrolled in recent clinical trials different from those observed in previous clinical trials?
  Noga SJ, Mo M, Dreiling L, Ozer H> ;J. Clin. Oncol.. 2009-05-20
• 21 citations
  Production Assistance for Cellular Therapies (PACT): four‐year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research pr...
  William Reed, Stephen J. Noga, Adrian P. Gee, Cliona M. Rooney, John E. Wagner, Jeffrey McCullough, David H. McKenna, Theresa L. Whiteside, Albert D. Donnenberg, Acaci...> ;Transfusion. 2009 Apr 1
• 39 citations
  A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemi...
  Jorge Sierra, Jeff Szer, Jeannine Kassis, Richard Herrmann, Mario Lazzarino, Xavier Thomas, Stephen J Noga, Nigel Baker, Roger Dansey, Alberto Bosi> ;BMC Cancer. 2008 Jul 10
• 8 citations
  Low Incidence of Neutropenic Events in Patients with Lymphoma Receiving First-Cycle Pegfilgrastim with Chemotherapy: Results from a Prospective Community-Based Study
  Stephen J. Noga, Janak K. Choksi, Beiying Ding, Lyndah Dreiling, Howard Ozer> ;Clinical Lymphoma & Myeloma. 2007 May 1
• 39 citations
  Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use
  Howard Ozer, Barry Mirtsching, Michael Rader, Susan Luedke, Stephen J. Noga, Beiying Ding, Lyndah Dreiling> ;The Oncologist. 2007 Apr 1
• A phase IV, open-label trial using bortezomib for retreatment of patients (pts) with multiple myeloma (MM) following an initial response to bortezomib.
  Druck M, Walters IB, Carloss H, Sood R, Leblanc AL, Noga SJ> ;J. Clin. Oncol.. 2006-06-20
• 584 citations
  Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
  Ricardo Spielberger, Patrick J. Stiff, William I. Bensinger, Teresa Gentile, Daniel J. Weisdorf, Tarun Kewalramani, Thomas B. Shea, Saul Yanovich, Keith Hansen, Stephe...> ;The New England Journal of Medicine. 2004 Dec 16
• Join now to see all

Abstracts/Posters

• Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
  Stephen J Noga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019